Several reports of MET amplification–mediated resistance to targeted therapies have emerged thereafter, including to anaplastic lymphoma kinase (ALK) inhibitors in ALK-rearranged NSCLC, cetuximab in colorectal cancers, and antiangiogenic therapies in glioblastoma (40–42). Here, MET is linked to glioblastoma.